Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-08-01 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (vice general manager) from the company. It includes a formal statement from the board and the effective date of resignation. There is no financial data, no report attached or referenced, and no mention of other types of filings such as annual reports or earnings releases. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-08-01 Chinese
天士力关于员工持股计划存续期届满暨终止的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expiration and termination of the company's employee stock ownership plans (员工持股计划). It details the basic situation of the first and second employee stock ownership plans, their purchase and lock-up periods, and the subsequent sale and termination of these plans. The document is a formal announcement by the company's board about the completion and termination of these plans, including compliance with regulatory guidelines. It does not contain financial statements, audit information, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or management report. It is a regulatory announcement about employee stock plans, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal disclosure to the market.
2025-07-23 Chinese
天士力关于药品注册申请进展的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding the withdrawal of a drug registration application with the National Medical Products Administration (NMPA) in China. It details the drug name, registration classification, reasons for withdrawal, and impact on the company. The document is short (1141 characters) and serves as a regulatory disclosure about the status of a drug registration application, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is an official regulatory announcement about a specific corporate event related to product registration progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-18 Chinese
天士力第九届董事会第10次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 10th meeting of the 9th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It details voting results on various company governance matters such as guarantee management, debt financing and liability management, performance contracts for 2025, and senior management compensation plans. The document is short (906 characters) and focuses on board meeting decisions and voting outcomes. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is not an announcement of shareholder voting results at a general meeting but rather a board meeting resolution announcement. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2025-07-15 Chinese
天士力关于全资子公司药品硫酸氨基葡萄糖胶囊获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's basic information, approval, and risk factors. The document is short (1105 characters) and serves as a formal public announcement about regulatory approval rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a regulatory announcement category related to compliance and approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-06-10 Chinese
天士力关于全资子公司药品托拉塞米注射液获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company TianShiLi Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary receiving a drug registration certificate for a pharmaceutical product (Torsemide Injection). The content focuses on the regulatory approval of a drug, its basic information, and risk warnings related to market uncertainties. There is no financial data, no mention of annual or quarterly reports, no management or board changes, no voting results, no earnings information, and no investor presentation. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-05-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.